ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
Publish Date: 2026-03-31 04:56:00
Source Domain: www.pharmaceutical-technology.com
Researchers at the 2026 ACC show baxdrostat lowers blood pressure in patients with uncontrolled hypertension with a favourable safety profile. Image credit: Brian A Jackson via Shutterstock.
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, researchers presented a meta-analysis of randomized trials assessing baxdrostat in patients with uncontrolled hypertension on standard therapy. The analysis combined three randomized controlled trials including 1,264 patients and evaluated blood pressure outcomes and safety.
Uncontrolled hypertension continues to drive cardiovascular events and organ damage despite broad use of multiple antihypertensive classes. Patients who remain above target blood pressure on standard combinations often require further treatment intensification, but current late-line options can be limited by tolerability, monitoring needs, and access.
The investigators conducted a systematic search across three databases up to September 2025 and included trials that randomized patients with uncontrolled hypertension to baxdrostat or control on top of background therapy. Baxdrostat is a selective aldosterone synthase inhibitor designed to reduce aldosterone production and downstream sodium retention while avoiding some of the off-target effects seen with mineralocorticoid receptor antagonists.
Across the three trials, baxdrostat reduced systolic blood pressure by 9.17 mm Hg compared with control, with narrow confidence intervals and no observed heterogeneity between studies….
